Russell Investments Group
VYNE icon

Russell Investments Group’s VYNE Therapeutics VYNE Stock Holding History

Russell Investments Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-187
Closed -$351 – 3803
2024
Q3 		$351 Hold
187
– – ﹤0.01% 3601
2024
Q2 		$368 Hold
187
– – ﹤0.01% 3520
2024
Q1 		$574 Hold
187
– – ﹤0.01% 3191
2023
Q4 		$435 Hold
187
– – ﹤0.01% 3134
2023
Q3 		$748 Hold
187
– – ﹤0.01% 3365
2023
Q2 		$759 Hold
187
– – ﹤0.01% 3339
2023
Q1 		$575 Sell
187
-1
-0.5% -$4 ﹤0.01% 3095
2022
Q4 		$506 Hold
188
– – ﹤0.01% 2882
2022
Q3 		$0 Hold
188
– – ﹤0.01% 2984
2022
Q2 		$1K Hold
188
– – ﹤0.01% 2871
2022
Q1 		$2K Hold
188
– – ﹤0.01% 2730
2021
Q4 		$3K Hold
188
– – ﹤0.01% 2986
2021
Q3 		$4K Hold
188
– – ﹤0.01% 3019
2021
Q2 		$11K Hold
188
– – ﹤0.01% 3187
2021
Q1 		$23K Sell
188
-1,620
-90% -$235K ﹤0.01% 3063
2020
Q4 		$205K Buy
1,808
+1,493
+474% +$188K ﹤0.01% 2750
2020
Q3 		$36K Buy
315
+134
+74% +$15.6K ﹤0.01% 3105
2020
Q2 		$22K Sell
181
-21
-10% -$2.84K ﹤0.01% 3050
2020
Q1 		$38K Sell
202
-200
-50% -$62.7K ﹤0.01% 2900
2019
Q4 		$133K Sell
402
-72
-15% -$24K ﹤0.01% 2823
2019
Q3 		$153K Sell
474
-190
-29% -$61.3K ﹤0.01% 2704
2019
Q2 		$286K Buy
664
+80
+14% +$39.6K ﹤0.01% 2429
2019
Q1 		$330K Buy
584
+39
+7% +$18.7K ﹤0.01% 2477
2018
Q4 		$162K Buy
+545
New +$244K ﹤0.01% 2637

Other funds holding VYNE

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Russell Investments Group's VYNE Position: Q4 2024 in Review

Russell Investments Group sold out of VYNE Therapeutics (VYNE) in Q4 2024, closing a stake of 187 shares — an estimated $351 sold.

Russell Investments Group first reported a position in VYNE in Q4 2018 and held it in 24 quarters. The position peaked at $330K in Q1 2019. 35 funds tracked by Wall St. Rank hold VYNE as of Q4 2024.

  • Russell Investments Group reported no remaining VYNE Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Russell Investments Group sold 187 VYNE Therapeutics shares in Q4 2024, an estimated $351.
  • Russell Investments Group first reported a position in VYNE Therapeutics in Q4 2018 and held it in 24 quarters.
  • Russell Investments Group's VYNE Therapeutics position peaked at $330K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2024.

Based on Russell Investments Group's 13F filing for Q4 2024, filed 13 Feb 2025.